Serum uric acid and resistance to antihypertensive treatment: data from the European Lacidipine Study on Atherosclerosis

Aim: Whether increased serum uric acid (SUA) favours resistance to antihypertensive drugs is not clear. Methods: The European Lacidipine Study on Atherosclerosis (ELSA) was a randomized, double-blind, multicenter trial comparing the effects of a 4-year treatment with either lacidipine or atenolol on progression of carotid atherosclerosis in patients with moderate hypertension. SUA was assessed at randomization and at the study end, office blood pressure (BP) was measured at each titration visit and every 6 months thereafter, ambulatory BP was measured at randomization and every year thereafter. Results: No difference was found in office and ambulatory BP reduction achieved after 1 and 4 years of treatment in baseline SUA tertiles. This was the case for both treatments. The percentage of patients with controlled office BP (<140/90mmHg) after 1 year (36.5, 34.2 and 33.8%, P¼0.56) and 4 years (39.9, 39.4 and 38%, P¼0.82) was not different in SUA tertiles. Similar results were obtained basing the analysis on the control of ambulatory BP (<130/80mmHg) or when data were analyzed taking into account SUA extreme values (>7 and <3.5mg/dl). The average and percentage changes of SUA (baseline-study end) were not different between patients who achieved or did not achieve office BP control (5.31+1.26 vs. 5.4+1.29mg/dl, P¼0.22 e 0.13+0.33 vs. 0.13+0.68, P¼0.87, respectively). This was the case also for control of ambulatory BP. Conclusion: In the ELSA study, SUA levels do not affect the responsiveness to antihypertensive treatment.